Ignyta (RXDX) Appoints Valerie Harding As Senior Vice President, Chemistry, Manufacturing, And Controls

SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, announced today that Valerie Harding, Ph.D., has been appointed to the newly-created role of Senior Vice President, Chemistry, Manufacturing, and Controls.

"We are fortunate to add Val to our executive team at this point in the growth of our company," said Jonathan Lim, M.D., Chairman and CEO of Ignyta. "Val's rich experience in pharmaceutical drug development and formulation, cultivated over more than 25 years at Pfizer, will be indispensable to us as we advance our commercialization plans for entrectinib and continue the development of the rest of our pipeline for the benefit of cancer patients."

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.